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ABSTRACT 18 
This “Perspective” reflects our observations of recent accomplishments made using SIFT-19 
MS. Only brief descriptions are given of SIFT-MS as an analytical method and of the recent 20 
extensions to the underpinning analytical ion chemistry required to realise more robust 21 
analyses. The challenge of breath analysis is given special attention because, when achieved, 22 
it renders analysis of other air media relatively straightforward. Brief overviews are given of 23 
recent SIFT-MS breath analyses by leading research groups, noting the desirability of 24 
detection and quantification of single volatile biomarkers rather than reliance on statistical 25 
analyses, for breath analysis is to be accepted into clinical practice. A “SWOT” analysis of 26 
SIFT-MS is made which should increase its utility for trace gas analysis. 27 
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 34 
Practitioners of selected ion flow tube mass spectrometry, SIFT-MS, have already eloquently 35 
described its unique strengths amongst the techniques available to gas phase analysis. So, in 36 
this “Perspectives” article we do not again describe the SIFT-MS technique in detail, but 37 
rather we simply briefly outline the physics and ion chemistry that underpin the technique in 38 
order to facilitate later criticisms, outline the major successes that differentiate it from other 39 
gas phase analytical techniques and then reveal the weaknesses of the technique and its 40 
shortcomings in analysis. An important aspect of this article will be to comment critically on 41 
recent endeavours to utilize SIFT-MS via its different modes of operation and to summarise 42 
results of some recent studies. We attempt to suggest more profitable directions for its future 43 
exploitation, especially when related to clinical diagnosis by breath analysis of specific 44 
diseases for which SIFT-MS has a special and possibly vital role to play.  In this regard,  45 
direct breath analysis and the detection and quantification of volatile disease “biomarkers” is 46 
of special interest for reasons that were touched upon in our recent short perspective [1] and 47 
will be expanded in the present article using topical examples of the work from different 48 
research groups. We will also reveal our own in-train developments of the instrumentation 49 
that are designed to increase versatility and value for trace gas analysis of humid samples of 50 
air, exhaled breath and the headspace of biogenic fluids such as bacterial cell cultures, which 51 
we anticipate will increase its appeal and attraction to researchers in other topics in which 52 
real time trace gas analysis has an important contribution to make. 53 
Selected ion flow tube mass spectrometry, SIFT-MS 54 
 Overview 55 
The principle and operation of SIFT-MS has been given in several reviews [2-5]. It is 56 
sufficient to say here that it relies on the chemical ionization by selected reagent ions, H3O+, 57 
NO+ and O2+•, of trace analyte compounds in air/breath samples introduced at a controlled 58 
flow rate into a helium-buffered flow tube. Reactions occur between the selected reagent ion 59 
and the composite analyte molecules that produce characteristic product (analyte) ions that 60 
are identified and their currents (count rates) measured by a downstream analytical mass 61 
spectrometer/detection system. The identified analyte ions are related to specific neutral trace 62 
compounds in the air/breath from an in-depth knowledge of the ion-molecule chemistry and 63 
their count rates, coupled with physical parameters such as carrier (helium) gas and sample 64 
gas flow rates, and are converted to concentrations of the neutral trace analyte molecules in 65 
the sample[6]. A proper appreciation of the complex ion chemistry occurring in SIFT-MS 66 
reactors, especially when humid samples are being analysed, is critical to achieving accurate 67 
trace gas analysis and we comment on some perceived short comings in this aspect later in 68 
this article.  69 
Two acquisition modes of reagent ion and analyte ion count rates are used, viz. the full scan 70 
mode, FSM, in which all ions within a chosen mass-to-charge ratio, m/z, are sampled and 71 
integrated over several scans, and the multiple ion monitoring mode, MIM, in which all the 72 
reagent ions and a few analyte ions are sampled and counted by rapidly switching the 73 
analytical mass spectrometer.  Using MIM, greater precision of measurement can be realized 74 
and changing concentration time profiles of several trace metabolites in single breath 75 
exhalation to be obtained simultaneously [6, 7]. Currently, SIFT-MS instrumentation can 76 
achieve reliable quantification down to one part-per-billion by volume, ppbv, in one second 77 
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of analyte ion integration [8, 9]. Even sub-ppbv sensitivity has been claimed [10, 11], 78 
typically using integration times in the order of minutes. Analyses of various media have 79 
been carried out using SIFT-MS by us and others [12-18], not least of exhaled breath [19-24], 80 
the results of which have been summarized in many research papers and some authoritative 81 
reviews [2-4, 25-29]. We later critically appraise some of the more recently reported studies.  82 
 83 
The extension of the SIFT-MS data acquisition approach was made possible by software 84 
developments that allow the count rates of all reagent and analyte ions to be determined at 85 
integer m/z values across the full mass spectral scan range available using the MIM approach. 86 
The m/z range accessible in the current Profile 3 instruments is up to 300. This allows 87 
statistical assessment of the mass spectral data and thus a careful critique of the use and 88 
misuse of the PCA approach to the identification of diagnostic biomarkers. 89 
 90 
 Ion chemistry 91 
As has been pointed out, SIFT-MS analysis depends on chemical ionisation using (precursor) 92 
reagent ions, H3O+, NO+ or O2+•, to generate the characteristic product (analyte) ions of the 93 
trace molecules in the sample being analysed [4].  The resulting analytical spectra are much 94 
simpler and more easily interpreted than those obtained using electron ionisation to analyse 95 
complex media like exhaled breath. Thus, m/z overlaps of analyte ions are fewer allowing 96 
trace compounds in air/breath samples to be unambiguously analysed more rapidly than when 97 
using pre-concentration and separation techniques in association with gas 98 
chromatography/mass spectrometry (GC-MS). This precious feature of SIFT-MS facilitates 99 
real-time trace gas analysis, including the analysis of single breath exhalations in real time, as 100 
discussed later.  101 
However, there is a sting in the tail! It is essential that the complex ion chemistry taking place 102 
in the flow tube that is the ion chemistry reactor be thoroughly understood and proper ion-103 
molecule kinetics data obtained to achieve accurate trace gas analyses. Such knowledge is not 104 
easily acquired; it has needed decades of research work by the authors to have gained 105 
sufficient understanding to conceive of and implement SIFT-MS as the reliable analytical 106 
technique it has become. Even under the truly thermalized conditions of SIFT-MS, the ion 107 
chemistry can be rich and several reaction mechanisms may occur that have to be understood 108 
in order to interpret the analytical mass spectra. Complications are minimised by the use of 109 
helium carrier gas, because it is relatively inert chemically, but even helium atoms are 110 
intimately involved in some of the ionic reactions, especially those involving the formation of 111 
adduct ions, as mentioned below. 112 
 113 
The reactions of the three available reagent ions are very different and each must be 114 
understood if these reactions are to be used for analysis. H3O+ ions react with most 115 
molecules, M, including volatile organic compounds (VOCs), by the process of proton 116 
transfer resulting in MH+ ions, but it is important to realise that for many organic molecules 117 
spontaneous dissociation of the nascent (MH+)* ions can occur, often with the ejection of an 118 
H2O molecule. Obviously, if this is not appreciated then gas analysis will be inaccurate and 119 
even meaningless. The analogous ion chemistry underpinning the PTR-MS drift tube is more 120 
complicated [8], given that both the reagent and analyte ions are suprathermal (kinetically 121 
excited) promoting break-up of the analyte ions in collisions with heavy nitrogen and oxygen 122 
carrier gas molecules rather than lighter helium carrier gas atoms used in SIFT-MS. We 123 
discuss this phenomenon later in relation to our recent development of our SIFDT-MS. NO+ 124 
ions react with VOCs by several defined mechanisms, including charge transfer producing 125 
M+ ions, hydride ion transfer producing (M-H)+ ions and by ion-molecule association 126 
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producing NO+M adduct ions. O2+• ions react by charge transfer with most molecules, which 127 
with small molecules like NH3 and NO is non-dissociative producing the parent radical cation 128 
(e.g. NH3+ and NO+). However, O2+• reacts with most VOCs producing two or more fragment 129 
ions, and this minimises its value as a SIFT-MS reagent ion. This critical ion chemistry 130 
knowledge has been acquired by many studies of the reactions of these three reagent ions 131 
with groups and homologous series of many biogenic VOCs, [5, 30-32] in order to build the 132 
kinetics library needed for SIFT-MS analyses. [6, 9] 133 
Detailed discussion of the relevant ion chemistry is given in the cited references. But it is 134 
vital now to discuss two aspects of it that are often not appreciated by those who attempt to 135 
advance SIFT-MS by increasing analytical sensitivity and to extend its application. These 136 
related to the analysis of very humid samples such as exhaled breath and the use of carrier 137 
gas other than inert helium, especially nitrogen. Inevitably, especially when exploiting H3O+ 138 
and NO+ reagent ions for analysis, hydrated ions of both the reagent ion efficiently form, viz. 139 
H3O+(H2O)1,2,3 and NO+(H2O)1,2, and the analyte ions, viz. MH+(H2O)1,2,3 and (M-140 
H)+(H2O)1,2. The hydrated reagent ions must be considered as additional reagent ions in the 141 
analysis and this is not a trivial task, because these cluster ions are continuously formed along 142 
the length of the flow tube and so the reaction times of these additional reagent ions have to 143 
be estimated. We have addressed these complicating aspects of SIFT-MS analysis in detail, 144 
and constructed appropriate analytical expressions that involve the rates of these hydration 145 
processes [6, 32, 33]. This would not have been possible without a detailed understanding of 146 
the ion hydration process we have acquired by many experimental investigations [30, 31]. 147 
Thus, trace gas analysis can now be achieved to acceptable accuracy in very humid samples, 148 
as we have demonstrated in several papers [9, 18, 28, 34, 35].  149 
A closely related phenomenon is the formation of weakly-bound adducts by the association 150 
of the reagent ions with the other abundant molecules of the sample gas i.e. N2, O2 and, in 151 
exhaled breath, CO2. Thus, adduct ions such as H3O+N2, H3O+CO2, NO+CO2, O2+•O2 and 152 
O2+•CO2 can clearly be detected in a mixture of the helium carrier gas and dry air. The danger 153 
is that these adduct ions may be isobaric with an analyte ion formed in the analysis of some 154 
common trace compounds in biogenic mixtures and then quantification can be compromised. 155 
For example, H3O+N2 ions are isobaric with protonated ethanol (m/z 47) and H3O+CO2 is 156 
isobaric with the monohydrate of protonated acetaldehyde (m/z 63). Whilst these two adduct 157 
ion species are very reactive, especially with H2O molecules, they are formed in the analysis 158 
of humid exhaled breath and must be accounted for to achieve accurate analyses. [36]. 159 
Similarly, the formation of O2+•CO2 (m/z 76) when using O2+• reagent ions to analyse CS2 in 160 
exhaled breath is a real problem (analyte ion in this case is CS2+) [37]. The formation of 161 
H3O+N2 will be particularly efficient when using nitrogen carrier gas that has been used in 162 
recent SIFT-MS analyses [38] or air as it is routinely used in PTR-MS [39, 40]. An essential 163 
point to make is that even though these adduct ions are not immediately detected by the 164 
downstream analytical mass spectrometer system, they are surely formed and undergo 165 
reactive loss especially with H2O molecules and other VOCs. These complications are 166 
generally not understood by most SIFT-MS and PTR-MS users and so for accurate analyses 167 
they must rely on calibration of their instrument using standard mixtures. But there are even 168 
dangers in this approach unless the calibrations are carried out at calibrant gas concentrations 169 
that are close to the concentrations in the sample mixtures to be analysed. It is our contention 170 
that over reliance on such calibrations without a good understanding of the analytical ion 171 
chemistry can lead to unrecognised inaccuracies. This is especially so when wide variations 172 
in trace gas (metabolite) concentrations occur in humid air/breath samples and when 173 
opportunistic variations in reactor conditions such as sample flow rate and variable E/N in 174 
PTR-MS are exploited ostensibly to improve analyses.  175 
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 176 
Finally, it is important to recognise that all users of SIFT-MS will not have a thorough 177 
background in ion chemistry and cannot be expected to appreciate all these nuances. 178 
However, to introduce a new compound into the analytical kinetics library requires an 179 
appreciation of this ion chemistry and thus will usually need the input of experts in the field.  180 
 181 
 Breath analysis 182 
SIFT-MS is now used to analyse air samples for trace VOCs in several areas of research, as 183 
listed in our recent reviews [2-4, 25-29]. However, it is in breath analysis where the real 184 
analytical challenges are revealed, because exhaled breath is supersaturated with water 185 
vapour, which most analytical techniques are not able to cope with when de-humidification is 186 
often required that can partially, which can partially or totally remove some trace compounds 187 
from the breath sample. But SIFT-MS not only copes with the high humidity but actually 188 
measures the humidity providing a very valuable method to check sample humidity (water 189 
vapour content), which for exhaled breath is always close to 6% by volume, and of sampling 190 
integrity [9, 41]. Thus, breath analysis is directed towards identifying abnormal 191 
concentrations of VOC metabolites, distinguishing endogenous from exogenous compounds 192 
and to detect, identify and quantify biomarker VOCs related to disease. Given that the 193 
concentrations of most volatile biomarkers in exhaled breath are low, often at parts-per-194 
billion by volume, ppbv, or lower, this is a real challenge that the analytical instrumentation 195 
must meet and provide sufficiently accurate and precise to be useful clinically. If this can be 196 
performed directly both in real time and on-line avoiding sample collection that and provide 197 
immediate analytical results, then the most reliable breath analyses can be obtained. Such is 198 
the promise of SIFT-MS, as is shown below by sample data.  199 
Unfortunately, so much breath analysis research is focused on efforts to simply identify 200 
volatile compounds of particular disease states by comparing the composition of breath from 201 
“healthy” subjects with breath from patients with particular disease states, paying too little 202 
attention to quantification that is essential to establish meaningful biomarkers. It is stating the 203 
obvious that it is of little value to inform a person that they have cholesterol in their blood 204 
without giving its concentration; the same should apply to breath biomarkers! Too often, 205 
most workers are apparently satisfied to reveal groups of breath biomarker compounds by 206 
statistical analysis of trace compound data derived from healthy/diseased groups of 207 
volunteers, rarely attempting to identify and quantify individual compounds. Such data are 208 
interesting and can be a guide to further research, but they are of little value to clinicians and 209 
are quickly archived. It is our contention that much more effort should be given to the 210 
identification and quantification of discrete breath biomarkers; in this we have had some 211 
success, as outlined later. It would be remiss not to mention that breath analysis is indeed 212 
used to effect in monitoring asthma via breath nitric oxide levels [42, 43] and in monitoring 213 
exhaled breath 13CO2 following the ingestion of 13C-labelled compounds to pinpoint and track 214 
specific metabolic disorders and diseases [44, 45]. Otherwise, the clinical return for the recent 215 
rapid increase in breath analysis research has so far been small, principally due to poorly 216 
directed research, some examples of which we describe in this article. 217 
But it is not our intention in this “Perspective” to diminish the contribution of other users of 218 
SIFT-MS in their efforts to progress breath analysis and especially those involved in the 219 
search for biomarkers that could make an important contribution to clinical diagnosis and 220 
therapy monitoring. Rather, it is to steer the work towards a more rapid and clinically 221 
profitable approach to the desirable objectives that we all passionately desire. As mentioned 222 
above, we concentrate on breath analysis but not exclusively, because SIFT-MS is being 223 
profitably used in other areas, notably environmental (air pollution) monitoring and food 224 
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flavour research that will briefly be referred to later and for which small instrumental 225 
development is also very desirable. 226 
 227 
Breath sampling and analysis is essentially a simple, non-invasive and painless procedure that 228 
can be accomplished easily even by babies and frail patients. Sample collection by exhalation 229 
into bags followed by off-line analysis has been most commonly used, which inevitably 230 
provides a mixture of breath from the alveoli and the respiratory airways. Attempts have been 231 
made to selectively collect end-tidal breath (sometimes inaccurately termed alveolar breath) 232 
using exhaled carbon dioxide monitoring. This may be worthwhile ultimately, but at the 233 
expense of more complex, less direct sampling procedures that can compromise the breath 234 
sample due to condensation and cross contamination from additional tubing and circuitry. So 235 
we doubt that such efforts are really useful at the current stage of breath research, since they 236 
deflect from the much more challenging analytical issues involved in the search for real 237 
biomarkers. It is suggested by some that this sampling approach can minimise contamination 238 
of the mouth-exhaled breath sample by compounds generated in the oral cavity. This is 239 
pertinent, but it does not stand thorough examination since the exhaled breath still passes 240 
through the mouth. Yet it is true that mouth generation is not taken sufficiently serious in 241 
breath sampling and mostly is deliberately ignored.  Surely, a better approach is to bypass the 242 
oral cavity by sampling breath exhaled via the nose? Of course, this presents an additional 243 
practical problem to breath sampling, and whilst not necessarily providing a true breath 244 
composition related to alveolar and airways origin only, it is a close approximation. We 245 
further address this situation below in relation to real time breath analysis that obviates breath 246 
sample collection and off-line analysis. 247 
 248 
Fig. 1 A schematic diagram of the Profile 3 SIFT-MS instrument indicating the major functional parts. 249 
Decreasing ion currents pass sequentially through the three orifices indicated. Both direct breath sampling and 250 
sampling from ambient air or liquid headspace are depicted. Reproduced from [4] with permission from RSC.251 
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 252 
Breath analysis in real time by SIFT-MS is achieved by displacing the ambient air from the 253 
entrance to the heated calibrated capillary with directly-exhaled breath (see Figure 1) whilst 254 
running the detection mass spectrometer in either the FS or the MIM mode. The sampling 255 
entry lines are held at around 70 C to inhibit surface adsorption of water vapour and 256 
condensable compounds. A disposable mouthpiece is used for mouth sampling of exhaled 257 
breath; inhalation through the mouth re-establishes ambient air at the capillary entrance for 258 
analysis. Several mouth exhalation/inhalation cycles are analysed for breath-by-breath 259 
consistency checks. Alternatively, breath sample collection into vessels for off-line analysis 260 
can be used, but water-soluble compounds such as ammonia can readily adsorb onto the 261 
vessel surfaces and thus distort the analysis. Bacterial filters must be used for on-line breath 262 
sampling from patients with infectious respiratory diseases. Typical data obtained for direct 263 
on-line breath sampling by SIFT-MS are shown in Figure 2 showing the well-defined 264 
exhalation time profiles and the derived concentrations of the several compounds that range 265 
from percentage levels (water vapour and carbon dioxide) to the ppbv levels of two trace 266 
metabolites (hydrogen cyanide and acetone) that carry the physiological and clinical data.  267 
 
 268 
Fig. 2 Time concentration profiles for water vapour and CO2 (in %) and acetone and HCN (in parts-per-billion 269 
by volume, ppb) for six sequential breath exhalations obtained using the MIM mode of the Profile 3 SIFT-MS 270 
instrument, indicating the remarkable breath-to-breath consistency in the derived concentrations of all four 271 
compounds. Also, indicated to the right, are the laboratory air concentrations of each compound. Reproduced 272 
from [4], with permission from RSC. 273 
274 
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 275 
What is so satisfying is that this sampling procedure can be easily modified to sample breath 276 
exhaled via the nose. Thus, a small vacuum pump is included in the SIFT-MS sampling line 277 
downstream in order to draw ambient air or exhaled breath across the entrance to the 278 
sampling capillary. The flow rate of air/breath must be adjusted to be much smaller than 279 
breath exhalation rates via the mouth or the nose to ensure that normal breath exhalations 280 
from the mouth and from the nose are not compromised. Then sampling of the exhaled breath 281 
from one nostril for about 10 s with both the second nostril and the mouth closed provides an 282 
on-line analysis of nose-exhaled breath. Closing both nostrils and sampling from the mouth 283 
indicates which compounds are predominantly produced in the oral cavity. Thus, analyses of 284 
specific selected compounds present in mouth-exhaled breath, nose-exhaled breath and 285 
mouth cavity air can be performed sequentially in real time in less than a minute. Such 286 
studies have provided very interesting data that show which compounds are predominantly 287 
produced in the oral cavity and those that are largely systemic. For example, ammonia and 288 
ethanol mostly originate in the oral cavity (influenced by oral hygiene) and acetone and 289 
isoprene are entirely systemic in origin. It is now apparent that much of the analyses carried 290 
out on mouth-exhaled breath are surely contaminated by orally-generated compounds and 291 
future studies must address this point. We have also demonstrated that collection of nose-292 
exhaled breath can be performed using a pump in the nose sampling line to inflate flexible 293 
bags, but it has to be appreciated that this can take a few minutes and so during the inhalation 294 
phase of breathing the sampled air will be diluted with laboratory air. This can be accounted 295 
for by normalising to the breath acetone level as measured directly in mouth exhalations and 296 
the laboratory air composition as measured during inhalations, according to the simple SIFT-297 
MS protocol outlined above. We have trialled this sampling procedure even by analysing the 298 
nose-exhaled breath of small babies with some success.  299 
 300 
 301 
Recent SIFT-MS studies: review and assessment  302 
The exploitation of SIFT-MS for trace gas analysis is growing in a number of fields and is 303 
limited currently mostly by the availability of affordable instrumentation. This undesirable 304 
situation needs to be rectified and we indicate the possible solution to this towards the end of 305 
this article. Even so, some hundreds of research papers have been published with SIFT-MS 306 
analyses as their focus and some reviews have been published that are a quick source of 307 
summary information [2-4, 25-29]. Unfortunately, some papers are uncritical and propagate 308 
some of the least desirable and unproductive approaches to SIFT-MS analyses. However, the 309 
results of much careful and thorough work have been reported notably by the groups of R. 310 
Dweik, C. Turner, B. Ross, G. Hanna in addition to our own contributions at Prague and 311 
Keele. But it must be said that the approaches of all these groups have their strengths and 312 
weaknesses; by critical appraisal, ways are variously suggested to better exploit SIFT-MS for 313 
trace gas analysis. We now briefly review and assess some of these studies that are largely 314 
directed towards disease detection, after which we address SIFT-MS through a SWOT 315 
analysis that, we hope, faithfully represents the current standing of SIFT-MS as a gas phase 316 
analytical method. 317 
 Ion chemistry: additional data 318 
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To begin, it is appropriate to again recognise the requirement of a proper understanding of the 319 
ion chemistry that occurs in the SIFT-MS reactor to realise reliable analyses of humid air. If 320 
there is a general criticism of SIFT-MS work in most laboratories it is that not enough 321 
thought is given to this ion chemistry and proper quantification of trace compounds, which 322 
can be disastrous in medical studies. So it is desirable, even essential, to confirm the nature of 323 
assumed analytic ions of specific compounds formed under the specific conditions of the 324 
particular SIFT-MS instrument by the use of their pure compounds to confirmed the ion 325 
chemistry involved. Whilst this requires more work, it is more likely to produce reliable 326 
results. We also take the view that to be certain of compound identification, parallel GC-MS 327 
measurements should be carried out which, whilst not totally fool proof, can increase 328 
confidence in compound identification. It also makes good sense to attempt to trace the likely 329 
biochemistry forming breath biomarkers. Too little attention is given to these difficult aspects 330 
and the risk is that erroneous compound identification may take place. 331 
Relevant ion chemistry studies continue to be reported, which can be of great help to SIFT-332 
MS practitioners. A good example is the recent work of Amelynck and his group [46, 47] in 333 
which great efforts have been made to identify isomeric forms of terpenoid aldehydes, 334 
highlighting the fact that many biogenic trace compounds have several structural isomers that 335 
ideally should be characterised in analysis. Similar comments apply to isobaric compounds 336 
that are often difficult to separate in SIFT-MS, but this problem can be alleviated by using 337 
both H3O+ and NO+, and perhaps O2+•, reagent ions to analyse the sample, exemplified by a 338 
detailed study of the reactions of seven hexanol isomers [31]. Non-isomeric yet isobaric ions 339 
can also be separated with careful thinking, this being illustrated by the quantification of 340 
acetaldehyde, dimethyl sulphide and carbon dioxide involving isobaric analyte ions [48]. A 341 
recent, exciting study involves the study of the ion chemistry of malondialdehyde (MDA, see 342 
Figure 3) that has been proposed to reflect free oxygen-radical lipid peroxidation. This has 343 
allowed a kinetic library entry to be constructed for MDA in SIFT-MS which allows, for the 344 
first time, the detection of gaseous MDA as generated by in vitro cell cultures [18]. This 345 
study illustrates the effort that is often required to extend SIFT-MS analysis to biogenic 346 
compounds, which include many carboxylic acids for which the kinetics database entries 347 
have recently been constructed [32]. 348 
 349 
Fig 3. A full scan mass spectrum obtained when the headspace of freshly synthesised malondialdehyde (MW 350 
72) water solution was analysed by SIFT-MS using NO+ reagent ions showing four characteristic product ions at 351 
m/z 71, 89, 102, 120; see text for further explanation. Reproduced from [18] with permission from Wiley.352 
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 353 
 Volatile metabolites in exhaled breath and released by cell cultures 354 
Many SIFT-MS studies have been directed towards the detection in exhaled breath of volatile 355 
metabolites related to particular disease states. Notable contributions have been made by the 356 
aforementioned groups.  Our approach to this potentially valuable disease diagnostic support 357 
has been to focus largely on the search for single compound breath biomarkers and with some 358 
success, as we review later. However, single volatile metabolite biomarkers of disease are 359 
considered by most workers in the field to be unlikely but why, given that there are numerous 360 
non-volatile blood single biomarkers routinely used for diagnosis? Hence, most breath 361 
researchers take a more pragmatic approach which is to identify groups of compounds that 362 
differentiate the composition of breath from patients with particular diseases from the breath 363 
of healthy controls.  364 
Very active amongst the groups exploiting SIFT-MS is that of Raed Dweik at Cleveland, 365 
USA who, in this way, has made a valiant effort to demonstrate the value of breath analysis 366 
by several pointed studies, including the analysis of breath volatile metabolites as a non-367 
invasive tool to diagnose chronic liver disease [49], non-alcoholic fatty liver disease in 368 
children [50], identifying unique “breathprint” in patients with inflammatory bowel disease 369 
(IBD) [51] and acute decompensated heart failure [52], “breathprints” in children with IBD 370 
[53] (see Figure 4) for obese children compared to lean children as controls [54, 55], children 371 
with juvenile idiopathic arthritis [56] and studies of breath volatile metabolites in patients 372 
with pouch disorders [57].  373 
374 
Fig. 4. Typical results of a SIFT-MS study aimed at discovery of combinations of VOCs discriminating between 375 
IBD patients and healthy controls [53]. (a) Visualisation of linear canonical discriminant analysis demonstrating 376 
that 21 pre-selected VOCs can classify patients with IBD or as healthy controls. (b) Receiver operating 377 
characteristic (ROC) curve analysis, demonstrating accuracy of predicting the presence of IBD by 1-octene, (E)-378 
2-nonene and 1-decene taken separately and in a linear model combination that gave the best area under the 379 
curve (AUC) of 0.96. Reproduced from [53] with permission from Wiley. 380 
Differentiation between healthy and patient groups relies heavily on statistical analyses and 381 
often involves the measured concentrations of common and abundant breath compounds such 382 
as ammonia, acetone and isoprene that generally have a wide biological variability, even in 383 
the exhaled breath of healthy people, therefore having questionable validity. These analyses 384 
a) b) 
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also often include rarer low concentration compounds that are sometimes difficult to 385 
definitely identify and quantify by SIFT-MS alone, especially when the ion chemistry 386 
complications in SIFT-MS analyses of humid breath described in the previous section are not 387 
fully appreciated. This is why we consider that parallel GC-MS (with pre-concentration 388 
techniques) are needed to support identification and quantification of low-level new 389 
compounds in exhaled breath. Whilst the derived results of this substantial body of research 390 
are thought-provoking, can they be more than just a prelude and a guide to further work and 391 
what is their value clinically at this early stage? Even the most carefully thought-out 392 
statistical analyses can lead to ambiguous and doubtful results, as we show later. A final 393 
comment relates to the use of the term “breathprint” for mass spectral patterns. If this is 394 
intended to be analogous with “fingerprint” it is misplaced, since in breath analysis use only a 395 
pattern is described and not the depth of the impression. It must be appreciated that for 396 
meaningful breath analysis in medicine the concentrations of the various biomarkers must be 397 
accurately measured.  398 
Similar wide-ranging research is being carried out by the group of George Hanna at Imperial 399 
College London, UK, currently with a sharp focus on the detection and quantification of 400 
biomarkers in the breath (and urine) of oesophageal-gastric (OG) cancer patients, their 401 
surgical speciality. In a series of paper involving SIFT-MS analyses of exhaled breath and the 402 
headspace of gastric fluid and urine [20, 22, 58-61], they have searched for volatile 403 
biomarkers of OG cancer, anticipating that such could greatly help the early diagnosis and 404 
follow-up therapy after surgery. SPME/GC-MS and ATD/GC-MS have been added to their 405 
analytical armoury to firm up trace compound identification. [1]. Again, heavy reliance is 406 
placed on statistical analysis to differentiate component VOCs of patient samples and 407 
controls, including the use of optimisation of ROC curves to achieve diagnostic accuracy. Yet 408 
these ROC curves were constructed from the concentrations of several VOCs in combination, 409 
a questionable procedure that we consider later with respect to SIFT-MS data on breath 410 
analysis obtained in our Prague laboratory. An interesting and potentially important aspect of 411 
their investigations is the involvement of higher-order aldehydes (C3-C10) in tumour 412 
biogenesis, research that combines aldehyde detection and genetic manipulation of tumour 413 
cells concurrent with investigations of C3-C10 aldehydes in the exhaled breath of healthy 414 
subjects  [62] This clever work holds real promise and signals a more imaginative approach 415 
to breath gas analysis by searching for the biochemical origins of the aldehydes. The 416 
pioneering work of this group in direct sampling of exhaled breath in the perioperative setting 417 
well demonstrates the real time analyses that are possible by SIFT-MS [7]. Recently, they 418 
have extended their research to the analysis of the exhaled breath of patients suffering from 419 
inflammatory bowel disease [63]. 420 
Claire Turner, formerly at the Silsoe Research Institute (SRI) and currently at the Open 421 
University, UK, is one of the original users of SIFT-MS for breath analysis [64-68]. The 422 
work of her research team has been varied and combines both the search for breath 423 
biomarkers using multivariate statistical methods and also the investigation of single 424 
biomarkers, notably acetone and its association with diabetes [69],  which has realised some 425 
interesting results. The work of the group is notable in that it exploits several analytical 426 
methods and compares the data obtained from specific studies, exemplified by the use of GC-427 
MS, HPLC-MS and SIFT-MS in conjunction with multivariate classification for the diagnosis 428 
of Crohn’s disease by urine analysis [70].  Recent work involves the development and use of 429 
portable breath sensor devices for monitoring diabetes and their quantitative validation using 430 
SIFT-MS [71], the analysis of the volatile faecal metabolome for screening of colorectal 431 
12 
 
cancer that showed hydrogen sulphide, dimethyl sulphide and dimethyl disulphide were 432 
apparently elevated in patients at high risk of colorectal cancer [72], and the analysis of  433 
 434 
Fig. 5. Typical results of a SIFT-MS study aimed at discovery of single volatile metabolites in faecal 435 
metabolome as biomarkers of colorectal cancer [72]. (a) Results of SIFT-MS analyses of faecal headspace 436 
collected from low risk and high risk colorectal cancer groups obtained using H3O+ reagent ions and the count 437 
rate of the analyte ion at m/z 35 (protonated hydrogen sulphide) (b) corresponding results for count rate at m/z 438 
90 (presumably a protonated nitrogen containing molecule). Reproduced from [72] under the Creative 439 
Commons Attribution.  440 
VOCs faecal samples from rats fed control diets  [73].  441 
The work of the group of Brian Ross in Ontario, Canada, another pioneer of SIFT-MS, takes 442 
the eye being the first to combine sample concentration techniques (TD) with real time SIFT-443 
MS analysis to improve detection sensitivity [10, 74, 75]. The group has also recognised the 444 
importance of nose-exhaled breath analysis, as emphasized in the previous section, and 445 
combined TD and SIFT-MS to analyse nose-exhaled and mouth-exhaled breath showing that 446 
mouth-exhaled hydrogen sulphide [76], a known neuromodulator or cofactor, is largely 447 
generated in the oral cavity [77]. This work is truly exploiting the strength of SIFT-MS and 448 
shows one of its real advantages in breath analysis research. They also carried out the first 449 
meaningful studies of aldehydes as biomarkers of lipid peroxidation [78] and the release of 450 
these compounds from brain and liver cells following dietary supplementation with n-3 451 
polyunsaturated fatty acids [79]. Their work has even reached towards food science [80] and 452 
plant and fungal science with the quantification of methanol both chemically and biologically 453 
generated from lignin [81]. 454 
SIFT-MS was conceived and developed at Keele by the authors subsequently with a major 455 
contribution to its development in Prague. During its continuous development as a research 456 
and commercial analytical tool it has been used in the manner original intended, which is as a 457 
real-time analytical technique that can uniquely contribute to the methods now available for 458 
trace gas analysis of ambient air and exhaled breath. Its development and much of the 459 
research work carried out by its exploitation up to 2011 by us and others are summarised in 460 
two major review papers [3, 5] and subsequent work is reviewed in more recent papers [26, 461 
28]. In relation to breath analysis, a major contribution has been the provision of 462 
concentration reference ranges of common breath metabolites, in close collaboration with the 463 
aforementioned Claire Turner [64]. These were constructed by direct on-line, real-time SIFT-464 
b) a) 
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MS analyses (obviating sample collection) of the exhaled breath of the healthy population. As 465 
far as disease detection is concerned, we have tried to focus on the detection and 466 
quantification of single breath biomarker compounds of specific diseases that, we believe, are 467 
most desirable, since they would be more readily utilized for clinical diagnosis and 468 
therapeutic monitoring. In this pursuit we have had some success, as summarised by the 469 
following: 470 
• Serendipitous detection of gaseous hydrogen cyanide (HCN) when analysing by 471 
SIFT-MS the volatile emissions from cultures of Pseudomonas aeruginosa (PA) 472 
bacteria derived from patients with cystic fibrosis (CF), initiated a decade of research 473 
at Keele and Prague on the presence of HCN in the headspace of in vitro cultures of 474 
different strains of PA and in the exhaled breath of patients with CF.  This has 475 
established HCN as a reliable single and discrete biomarker of PA infection of the 476 
airways and lungs [29, 82-86] . 477 
• During this SIFT-MS PA/HCN research it was noticed that methyl thiocyanate was 478 
also emitted by PA cultures, its positive identification being confirmed by the analysis 479 
of the culture headspace with SPME/GC-MS following which SIFT-MS was used to 480 
quantify this VOC. [87, 88]. This was the first demonstration of the parallel use of 481 
SIFT-MS and GC-MS for trace gas analysis, a procedure that we now adopt routinely 482 
in the analysis of biogenic media and which we strongly encourage others to  adopt. 483 
• Detailed studies of exhaled breath of patients with Crohn’s disease (CD) and 484 
ulcerative colitis (UC) have revealed elevated levels of n-pentane relative to healthy 485 
controls [89, 90]. This required a detailed challenging study of the ion chemistry 486 
involved in n-pentane detection and quantification by SIFT-MS and which now 487 
allows this hydrocarbon to be detected in very humid breath, which can ultimately 488 
assist the non-invasive screening of inflammatory processes such as CD and UC. 489 
• During a collaborative study with clinicians focused on the composition of exhaled 490 
breath from those suffering from gastroesophageal reflux disease (GERD), it was 491 
discovered that the only VOC elevated in their breath relative to controls was acetic 492 
acid. Again, both SIFT-MS and GC-MS were exploited for this study. This indicates 493 
that breath acetic acid may be a useful indicator of GERD and other conditions that 494 
result in a lowering of pH of the lining of the airways [21]. It is exciting to note that in 495 
a very recent study (as yet unpublished), acetic acid is observed to be greatly elevated 496 
in the exhaled breath of cystic fibrosis patients, which may have important 497 
implications to the treatment of this disease. 498 
• Methane is present in the exhaled breath of all human beings and, along with 499 
hydrogen, when elevated it is a reflection of gut bacterial overload. We have 500 
developed SIFT-MS to quantify breath methane on-line in single breath exhalations 501 
using the slow reaction of O2+• reagent ions with methane [91]. Based on this work, 502 
breath methane concentration profiles have been constructed during exercise on an 503 
ergometer using the analogous PTR-MS real time analytical method [92], ostensibly 504 
providing a detector of gut bacterial overload. 505 
• As the expected new innovators of SIFT-MS-type instrumentation, we must not 506 
remain complacent. Thus, thoughts are continuously directed to improving compound 507 
identification and analytical sensitivity. For the former, we consider the idea of 508 
introducing TOF-MS higher resolution analysis to differentiate isobaric ions, but this 509 
would not be a panacea [8] and would greatly increase the cost of instrumentation. To 510 
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increase analytical sensitivity, new approaches to the thermal desorption of volatile 511 
compounds extracted from breath by sorbent tubes and its direct link to SIFT-MS are 512 
under development in Prague. Whilst acknowledging that the precious real-time direct 513 
analysis of exhaled breath and biogenic fluid headspace will be compromised, we 514 
believe that this will ultimately improve accuracy of quantification and simplify 515 
remote breath sample collection, transport and storage. Further to these developments, 516 
we have commenced research in the area of selected ion flow drift tube mass 517 
spectrometry, SIFDT-MS, which has some distinct advantages over SIFT-MS due to 518 
the inclusion of a low intensity drift field in the analytical reactor whilst retaining all 519 
the features of rapid analysis and immediate quantification [93, 94] (see Figure 6). 520 
 521 
Fig. 6. Schematic drawing of the selected ion flow-drift tube, SIFDT, apparatus recently developed in Prague. In 522 
this representation the sample gas introduction setup is represented by a glass vial containing 10 mL of liquid 523 
water through which dry synthetic air or laboratory air is introduced but direct or bag samples of breath can be 524 
readily introduced. Note that the speed of the helium carrier gas is reduced by a restrictive aperture between the 525 
flow-drift tube compartment and a scroll pump in this case. Reproduced from [94] with permission from ACS. 526 
The New Zealand groups (Malina Storer; Michael Epton) have made various contributions to 527 
breath research using the commercial SIFT-MS instruments Voice 100 and 200 (Syft 528 
Technologies, New Zealand), including both off-line and on-line measurement of exhaled 529 
HCN in relation to PA infection [95, 96], acetone in relation to diabetes [97] and critical 530 
illness [98]. They have also carried out breath testing in the workplace, particularly for 531 
acetonitrile exposure, the persuasive results of which are shown in Figure 7 [99]. A final 532 
development of note by Syft Technologies is the use of a SIFT-MS device Voice 200 loaded 533 
on a mobile van, which has been used for monitoring ambient air and exhaled breath for 534 
aromatic hydrocarbons to assess exposure to these compounds [100]. 535 
536 
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 537 
 538 
 539 
Fig. 7. Acetonitrile concentration measured by SIFT-MS in the exhaled breath of people who spent time 540 
working in a chemistry department laboratory where acetonitrile was used as a solvent. Reproduced with 541 
permission from IOP from [99]. 542 
Some achievements using SIFT-MS in other areas 543 
The various areas in which SIFT-MS analysis is exploited are tabulated and reprised in a 544 
recent review [26] so they need not be discussed in detail here. However, in addition to breath 545 
research, worthy of mention is the significant work carried out in analysing VOCs from food 546 
flavours and processed food, largely by Sheryl Barringer in Ohio, USA [15, 101-104] and M 547 
Monica Flores in Valencia, Spain [105, 106]. Interesting work has also been done on the 548 
deodorization of breath following the ingestion of raw garlic by various food and food 549 
components, essentially to remove the odorous organosulphur compounds. It was observed 550 
that the enzymatic activity, of polyphenolic compounds and the acidity of specific foods may 551 
cause a reduction of these volatiles, but chlorophyll does not cause a deodorization effect. 552 
[107] 553 
Studies of VOCs emitted by mammalian and bacterial cell cultures have been carried out in 554 
several laboratories following the early work [108-112] , but it would neither do justice nor 555 
be appropriate to summarise these detailed programmes here; rather, the reader is referred to 556 
recent papers on the subject [12, 108, 113-117]. But it is important to state that SIFT-MS real 557 
time analysis of the VOC emissions, including real time measurements during the evolution 558 
of bacterial cultures [118, 119], is ideal for these studies since it avoids sample collection and 559 
can be carried out  over long (incubation) time periods. 560 
  561 
 562 
The strengths, weaknesses, opportunities and threats 563 
The strengths, weaknesses, opportunities and threats (SWOT) of and to SIFT-MS are worth 564 
analysing as we perceive them.  565 
The strengths of SIFT-MS are articulated throughout this article. It is a powerful method for 566 
real-time breath analysis, ambient air analysis and the analysis of cell cultures headspace. It is 567 
an analytical method that uniquely can accurately and reliably measure concentrations of 568 
identified biomarkers of diseases in exhaled breath. To be useful clinically, such 569 
measurements must be objective and reproducible in all laboratories and clinics throughout 570 
the world, a requirement that analytical methods such as SPME/GC-MS can rarely fulfil 571 
without tedious and careful calibration. This is vital and important if reference ranges of 572 
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breath metabolites are to be established in the same sense that  are other crucial biomarkers 573 
such as blood pressure and cholesterol levels are accepted for health monitoring and control. 574 
The weaknesses of SIFT-MS relate to the limit of quantification, the practical lower limit 575 
being at about 1 ppbv in 1 second for real-time acceptably accurate analyses of trace 576 
metabolites in exhaled breath, and to the positive identification of unknown neutral trace gas 577 
analytes at characteristic analyte ions m/z values above 100 and beyond. Lower limits of 578 
sensitivity have been reported for specific trace compounds in air but not yet realised for 579 
general use [11]. 580 
 581 
Thus, identification of isobaric and isomeric compounds is generally not possible, but the 582 
incorporation of TOF-MS could help. The operation of SIFT-MS instruments and data 583 
interpretation is not easy for technicians, scientists and health professionals that do not have 584 
knowledge of mass spectrometry and ion chemistry. To alleviate these weaknesses offers a 585 
real challenge to the future development of SIFT-MS-type devices. 586 
Thus, there are obvious opportunities for instrumental development such as the improvement 587 
of analytical sensitivity and the reductions in size and cost, but importantly retaining the 588 
striking and unique features of real-time analyses and accurate quantification of trace 589 
compounds. These developments are now in train in our Prague laboratory which, when 590 
realised, will widen the exploitation of SIFT-MS in other areas of research and commerce 591 
such as, for example, in the surgeries of general practitioners where wide screening by real-592 
time breath analysis could be carried out routinely and non-invasively for abnormal levels of 593 
disease-related breath metabolites.  594 
 595 
The threats that are evident to the wider use of SIFT-MS in medicine largely revolve around 596 
the reluctance of clinicians to adopt breath analysis as an aid to clinical diagnoses and 597 
therapeutic monitoring even though it has great potential as a non-invasive diagnostic; this is 598 
de-motivating to research workers in this field. Their negative, often justified assessment is 599 
partly due to the failure of research workers in breath analysis to convincingly articulate their 600 
experimental work and to the premature reporting of inconsistent results that often defy 601 
previous work without explanation. There is even the tendency to ignore the essential 602 
requirements for biomarker identification and accurate quantification for the sake of 603 
expediency and the urge by institutional management authorities for more publications 604 
(“publish and be damned”). Additionally, the adoption of inadequate analytical methods that 605 
fail to identify genuine biomarkers and the excessive reliance on statistics to assess unreliable 606 
data is a major problem, as highlighted previously. Nevertheless, we believe that direct on-607 
line SIFT-MS analysis offers the best hope for the acceptance of breath analysis into medical 608 
practice. It is perhaps significant that the wider growing use of SIFT-MS is in the less 609 
stringent areas of food monitoring and ambient trace gas detection as alluded to previously. 610 
 611 
Summary remarks 612 
What are the essential points that can be extracted from the above “Perspective”? They are 613 
that SIFT-MS is a unique and valuable addition to ambient trace gas analysis in that direct 614 
on-line analysis of volatile compounds in ambient air and very humid exhaled breath can be 615 
achieved. This offers a rapid, direct non-invasive analytical method to assist clinical 616 
diagnosis and therapeutic monitoring that is not offered by breath sample collection and off-617 
line GC-MS analysis. SIFT-MS analysis is relatively straightforward for the analysis of 618 
known trace compounds present at easily measurable concentrations. But when searching for 619 
and accurately analysing less common trace gases or breath metabolites, it must be used with 620 
aforethought with an eye on the underlying physics and chemistry in order to avoid serious 621 
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errors that would damn this analytical method in the eyes of clinicians. An important point to 622 
stress is that the over reliance on statistical analysis when interpreting arrays of SIFT-MS 623 
(and GC-MS) data can often lead to misleading and even false results and deductions, which 624 
obviously is disastrous in medicine. Too little effort is given to the identification and accurate 625 
quantification of single breath metabolites that can be used as meaningful diagnostic 626 
biomarkers. Too much reliance is placed on patterns of several volatile metabolites that are 627 
collectively labelled as biomarkers, which will never to be exploited by clinicians. The 628 
strengths and weaknesses of SIFT-MS are made clear in this article, and the requirements for 629 
instrumental improvement are spelled out that, if achieved, will remove the threats to the 630 
extension and wider use of SIFT-MS in medicine and other areas. 631 
Future perspective 632 
A necessary development of SIFT-MS is the improvement of trace compound identification 633 
and analytical sensitivity. This is partly envisaged by commencing development of new 634 
method, SIFDT-MS, that includes a drift–tube reactor, and the inclusion of thermal 635 
desorption elements for analyses of samples collected on sorbent tubes. 636 
 637 
It is anticipated that small hand-held instruments will be developed involving optical 638 
spectroscopy and solid state sensors to target individual biomarker molecules. 639 
  640 
When further analyte ion resolution is needed to separate isobaric ions then the combination 641 
of SIFT-MS with GC-MS will be further exploited to guarantee more certain compound 642 
identification and accurate quantification of biomarkers that can be adopted in medicine. 643 
 644 
Further efforts must be made to identify and quantify single breath biomarkers. When 645 
compound “profiling is the only way forward then better understanding of statistical methods 646 
for data interpretation need to be investigated. 647 
 648 
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Executive summary 649 
• As the need for the analysis of more complex trace compounds arises, the 650 
challenges to SIFT-MS analyses grow and more detailed ion chemistry 651 
investigations are required, especially associated with the involvement of adduct 652 
ion formation. To obtain more certain compound identification, it is strongly 653 
advised to combine GC-MS and SIFT-MS analyses, especially when isobaric and 654 
isomeric compounds are involved. 655 
• The analysis of trace gases (metabolites) in humid exhaled breath presents a 656 
serious analytical challenge. SIFT-MS provides the best route to direct, non-657 
invasive real time analysis of single breath exhalations.  658 
• Guidance as to the best approach to breath analysis and examples of the data that 659 
can be obtained by SIFT-MS are given as a guideline to the required quality. 660 
• Reliance on statistical analyses to distinguish “normal breath” from “diseased 661 
breath” should be diminished with greater focus on the identification of single 662 
biomarkers of disease that are much more likely to be adopted as useful 663 
biomarkers of disease. 664 
• SIFT-MS has been exploited to monitor volatile organic compounds from food 665 
and food products in real time and those released by mammalian and bacterial cell 666 
cultures in vitro. 667 
• Strengths, weaknesses, opportunities and threats (SWOT analysis) in SIFT-MS is 668 
given, an appreciation of which will further establish it as a valuable method in 669 
the panoply of analytical methods being developed for gas analysis. 670 
 671 
672 
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